Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Sandro Pignata, Giovanni Scambia, Antonella Savarese, Enrico Breda, Paolo Scollo, Rocco De Vivo, Emanuela Rossi, Vittorio Gebbia, Donato Natale, Filomena Del Gaizo, Emanuele Naglieri, Antonella Ferro, Pietro Musso, Alfonso Maria D'Arco, Roberto Sorio, Carmela Pisano, Massimo Di Maio, Giuseppe Signoriello, Annalisa Annunziata, Francesco Perrone, MITO Investigators, Sandro Pignata, Giovanni Scambia, Antonella Savarese, Enrico Breda, Paolo Scollo, Rocco De Vivo, Emanuela Rossi, Vittorio Gebbia, Donato Natale, Filomena Del Gaizo, Emanuele Naglieri, Antonella Ferro, Pietro Musso, Alfonso Maria D'Arco, Roberto Sorio, Carmela Pisano, Massimo Di Maio, Giuseppe Signoriello, Annalisa Annunziata, Francesco Perrone, MITO Investigators

Abstract

Background: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned.

Methods: Patients with ovarian cancer (stage Ic-IV), aged < 75 years, ECOG performance status <or= 2, were randomized to carboplatin AUC 5 plus paclitaxel 175 mg/m2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0.

Results: The pre-planned safety analysis was performed in July 2004. Data from the first 50 patients treated with carboplatin plus pegylated liposomal doxorubicin were evaluated. Median age was 60 years (range 34-75). Forty-three patients (86%) completed 6 cycles. Two thirds of the patients had at least one cycle delayed due to toxicity, but 63% of the cycles were administered on time. In most cases the reason for chemotherapy delay was neutropenia or other hematological toxicity. No delay due to palmar-plantar erythrodysesthesia (PPE) was recorded. No toxic death was recorded. Reported hematological toxicities were: grade (G) 3 anemia 16%, G3/G4 neutropenia 36% and 10% respectively, G3/4 thrombocytopenia 22% and 4% respectively. Non-haematological toxicity was infrequent: pulmonary G1 6%, heart rhythm G1 4%, liver toxicity G1 6%, G2 4% and G3 2%. Complete hair loss was reported in 6% of patients, and G1 neuropathy in 2%. PPE was recorded in 14% of the cases (G1 10%, G2 2%, G3 2%).

Conclusion: This safety analysis shows that the adopted schedule of carboplatin plus pegylated liposomal doxorubicin given every 3 weeks is feasible as first line treatment in ovarian cancer patients, although 37% of the cycles were delayed due to haematological toxicity. Toxicities that are common with standard combination of carboplatin plus paclitaxel (neurotoxicity and hair loss) are infrequent with this experimental schedule, and skin toxicity appears manageable.

References

    1. Mc Guire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with placlitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6. doi: 10.1056/NEJM199601043340101.
    1. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708. doi: 10.1093/jnci/92.9.699.
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200. doi: 10.1200/JCO.2003.02.153.
    1. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of cisplatin and paclitaxel versus carboplatin and paclitaxel in advanced ovarian cancer. J Clin Oncol. 2000;18:3084–92.
    1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–29.
    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysis. J Clin Oncol. 2002;20:1248–59. doi: 10.1200/JCO.20.5.1248.
    1. Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE, Young RC. Inhibition of human ovarian cancer colony formation by Adriamicin and its metabolites. Cancer Res. 1980;40:4109–12.
    1. Ovarian Cancer Meta-Analysis Project Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. J Clin Oncol. 1991;9:1668–1674.
    1. A'Hern R, Gore ME. The impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 1995;13:726–32.
    1. Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993;72:3671–75. doi: 10.1002/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>;2-U.
    1. Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB. Doxorubicin encapsulated in strerically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumors xenografts. Cancer Res. 1996;56:3743–6.
    1. Vaage J, Donovan D, Uster P, Working P. Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer. 1997;75:482–6.
    1. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxoribicin in refractory ovarian cancer. Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987–93.
    1. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum-paclitaxel refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093–100.
    1. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Analysis of toxicities and predictors of outcome. Cancer. 2001;91:90–100. doi: 10.1002/1097-0142(20010101)91:1<90::AID-CNCR12>;2-A.
    1. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–22.
    1. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30–49 Investigators Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8. doi: 10.1016/j.ygyno.2004.07.011.
    1. Ferrero JM, Weber B, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E. Caelyx and Carboplatin in patients with advanced ovarian cancer in late relapse (>6 months): late results of a GINECO phase II trial [abstract] Proc Am Soc Clin Oncol. 2004;23 53 (Abstr 5022)
    1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–56.
    1. National Cancer Institute – Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 April 30, 1999
    1. du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) Ann Oncol. 2006;17:93–6. doi: 10.1093/annonc/mdj032.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅